Key takeaways
What matters most
- One studied topical spray improved hair count compared with placebo and produced a numerical result close to oral finasteride over 24 weeks.
- Lower blood exposure with the tested spray did not mean zero absorption or zero chance of systemic effects.
- The United States has an approved oral finasteride product for male pattern hair loss but no FDA approved topical finasteride product.
Topical and oral finasteride act on the same hormone pathway, but they are not a simple one for one swap. A phase three trial found that one specific topical spray increased target area hair count compared with placebo after 24 weeks. The numerical change was close to the oral finasteride reference group.
That does not prove that every compounded liquid, gel, or spray works like the product in the trial. It also does not prove that topical and oral finasteride are equal for every person. Formulation, amount applied, scalp area, absorption, and product quality can all differ.
The trial randomized 458 adult men with androgenetic alopecia. At week 24, the adjusted mean change in target area hair count was 20.2 hairs with the topical spray and 6.7 hairs with placebo. The oral reference result was numerically close to the topical result.
The careful wording matters. The trial was designed to show that the topical spray performed better than placebo and to compare exposure with oral finasteride. It was not a broad test of every topical product, and the research was funded by companies connected to the spray. The result is useful evidence for that formulation, not a promise for another one.
In the same study, maximum finasteride levels in plasma were more than 100 times lower with the topical spray than with oral finasteride. Mean serum DHT fell by 34.5 percent with the spray and 55.6 percent with the tablet.
Those findings support a lower systemic exposure with the tested spray, but they do not support calling it risk free. The FDA says skin absorption is expected with compounded topical finasteride and has received reports of sexual, mood, sleep, and other symptoms. Topical products can also cause local irritation and can transfer to another person through contact.
Oral finasteride 1 milligram is approved in the United States for male pattern hair loss in men. There is currently no FDA approved topical finasteride product. Compounded topical products are not reviewed by the FDA for safety, effectiveness, or quality before marketing. Some finasteride skin sprays are authorized in parts of Europe, so regulatory status also depends on the country and formulation.
United States labeling lists sexual adverse reactions for oral finasteride. European regulators also advise people taking 1 milligram tablets for hair loss to seek medical advice about sexual symptoms and to stop and contact a doctor if mood changes occur. Finasteride exposure during pregnancy can harm a male fetus. The FDA warns that topical products create an added transfer concern because there is no protective tablet coating.
A progress record cannot choose between topical and oral finasteride. That decision belongs with a licensed clinician who can consider the diagnosis, product, medical history, pregnancy exposure risk, and possible adverse effects.
If a clinician prescribes finasteride, record the exact form, label or prescription directions, real start date, routine changes, personal observations, and a repeatable photo baseline. Keep those facts separate from your interpretation. A photo can show appearance under matched conditions, but it cannot measure DHT or prove that a treatment caused a change.
